Search Results1-20 of  30

  • 1 / 2
  • Muro Kei ID: 9000264861945

    Articles in CiNii:1

    • Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer (2014)
  • Muro Kei ID: 9000266435624

    Articles in CiNii:1

    • A phase Ⅱ study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus : The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) (2014)
  • Muro Kei ID: 9000329006934

    Articles in CiNii:1

    • Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW : a randomized clinical trial in second-line treatment of gastric cancer (2016)
  • Muro Kei ID: 9000361678910

    Articles in CiNii:1

    • Comprehensive Registry of Esophageal Cancer in Japan, 2010 (2017)
  • Muro Kei ID: 9000380492858

    Articles in CiNii:1

    • Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naive metastatic gastric/gastroesophageal junction cancer (2018)
  • Muro Kei ID: 9000396179069

    Articles in CiNii:1

    • Comprehensive Registry of Esophageal Cancer in Japan, 2011 (2018)
  • Muro Kei ID: 9000398634466

    Articles in CiNii:1

    • Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan (2018)
  • Muro Kei ID: 9000399574888

    Articles in CiNii:1

    • Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer : an exploratory analysis of the phase Ⅲ ABSOLUTE trial (2019)
  • Muro Kei ID: 9000401420817

    Articles in CiNii:1

    • A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) (2019)
  • Muro Kei ID: 9000403259781

    Articles in CiNii:1

    • Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer : the JAVELIN Solid Tumor JPN trial (2019)
  • Muro Kei ID: 9000403259806

    Articles in CiNii:1

    • Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase Ⅱ nonrandomized KEYNOTE-059 study (2019)
  • Muro Kei ID: 9000403290252

    Articles in CiNii:1

    • Comprehensive registry of esophageal cancer in Japan, 2012 (2019)
  • Muro Kei ID: 9000403921182

    Articles in CiNii:1

    • Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G (2016)
  • MURO Kei ID: 9000001019634

    Department of Internal Medicine, National Cancer Center Hospital East (1996 from CiNii)

    Articles in CiNii:1

    • Treatment for Locally Advanced Esophageal Carcinoma Complicated by Fistulas: Case Report (1996)
  • MURO Kei ID: 9000001122315

    Department of Clinical Oncology, Aichi Cancer Center Hospital (2012 from CiNii)

    Articles in CiNii:10

    • Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer (2003)
    • Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer (2004)
    • Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil (2004)
  • MURO Kei ID: 9000006418032

    Articles in CiNii:17

    • Chemoradiotherapy for esophageal cancer (2009)
    • Role of medical treatment for esophageal cancer: possibility of new anticancer agents and molecular targeting drugs (2007)
    • Chemotherapy for outpatient in esophageal cancer (2007)
  • MURO Kei ID: 9000019982337

    Department of Clinical Oncology, Aichi Cancer Center Hospital (2011 from CiNii)

    Articles in CiNii:1

    • Induced Nausea and Vomiting Induced by mFOLFOX6 and FOLFIRI with Advanced Colorectal Cancer: A Retrospective Survey (2011)
  • MURO Kei ID: 9000107314504

    Division of GI Oncology, National Cancer Center Hospital (2004 from CiNii)

    Articles in CiNii:1

    • Regioselective Monosulfation and Disulfation of the Phytoestrogens Daidzein and Genistein by Human Liver Sulfotransferases (2004)
  • MURO Kei ID: 9000252831231

    National Cancer Center Research Institute (1997 from CiNii)

    Articles in CiNii:1

    • INACTIVATION MECHANISM OF HUMAN DIHYDROPYRIMIDINE DEHY DROGENASE BY 5-(2'-BROMOVINYL)URACIL, A METABOLITE OF THE ANTIVIRAL, SORIVUDINE (1997)
  • 1 / 2
Page Top